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Abstract 
The scientific community continuously strives to get new disease models, to discover early markers or 
novel therapeutic approaches, improving the diagnosis and prognosis of several human pathologies. 
Parkinson’s Disease (PD) is characterized by a long asymptomatic phase, characterized by a selective loss 
of dopaminergic neurons. Recently, the human Periapical Cyst-Mesenchymal Stem Cells (hPCy-MSCs) 
have been differentiated in functional dopaminergic neurons: such oral-derived MSCs and the 
hPCy-MSCs-derived exosomes may represent a strategic and useful in vitro study-model, as well as 
intriguing therapeutic carriers. Circadian rhythm (CR) alteration variously impacts on PD pathways: an 
interesting research target is represented by the analysis of the exosomes released by dopaminergic 
neurons, derived from neural-differentiated hPCy-MSCs, after having reproduced in-vitro PD-like 
conditions. This review aims to describe the crosstalk among some aspects of circadian rhythm related to 
the onset of PD and the exosomes released by cells of PD patients. More in detail: the first part of this 
article will describe the main characteristics of circadian rhythm and the involvement of the exosomes 
found to be effective in the pathogenesis of PD. Finally, the authors will suggest how those exosomes 
derived from dopaminergic neurons, obtained by oral-derived stem cells (hPCy-MSCs) may represent a 
smart model for the in vitro research on PD, to find new biomarkers, to test new drugs or, fatally, to find 
new pathways applicable in future therapeutic approaches. 
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Introduction 
Circadian rhythm is an endogenous process that, 
through complex cellular and molecular networks, 
regulates the organism's behavior following the sleep- 
wake cycle, and repeats approximately every 24hours. 
The circadian rhythm allows complex organisms to be 
able to sustain all such environmental changes that 
regularly occur during the light-dark cycles, thus 
impacting on alimentation, metabolisms, movement, 
and immunological reply to pathogens [1]. 
Clock genes commonly regulate the circadian 
rhythm: they are expressed by cells located in the 
suprachiasmatic nucleus (SCN), in the hypothalamus. 
These genes act as a regulatory system that modulates 
all the circadian mechanisms, working within the 
complex organisms [2]. In mammals, the circadian 
clock follows a hierarchical organization: in fact, the 
suprachiasmatic nucleus is stimulated by light signals 
that are converted into electrical signals within the 
retina; such electrical information is then transduced 
to cells and organs, through the activation of the 
“secondary oscillators” working as local effectors in 








The circadian system is self-sustainable, and it 
regularly works across the day under stable and 
physiological conditions; nevertheless, it may be 
impaired by those entraining cues called “zeitgebers” 
[1]. 
At the molecular level, several transcriptional 
“feedback loops” can regulate the secondary 
oscillators: this set of proteins may act as positive 
(CLOCK, BMAL1) or negative (CRY1-2, PER1-3) 
transcription factors, upon binding to E-box (like) 
enhancer elements. The alteration or loss of clock 
genes results in a consequent impairment or loss of 
circadian rhythm [4]. 
Altered circadian rhythms are also associated 
with several human metabolic diseases, including 
type-2 diabetes and cardiovascular diseases, which 
represent a significant risk to public health. The 
molecular signal transduction pathways that mediate 
between stress responses and peripheric organs 
rhythms are aimed to maintain metabolic homeostasis 
under different conditions [5]. 
Numerous evidences have demonstrated that 
there are close and multilevel interactions between 
neurodegenerative pathologies and the alteration of 
the circadian rhythm.  
More in details, the circadian genes can impact 
on the tyrosine hydroxylase, the controlling enzyme 
aimed to modulate the dopamine synthesis; such 
pathway is regulated by the circadian locomotor cycle 
kaput (Clock) gene. Moreover, the circadian genes 
may also affect the dopaminergic activity in the 
ventral tegmental area of the brain, and dopamine is 
conversely able to regulate some Clock genes with a 
feedback mechanism [6]. In fact, dopamine is able to 
upregulate the transcriptional activity of Clock/Bmal 
complex: this action is carried out by an increase of 
the phosphorylation of transcriptional coactivator 
cAMP-responsive element-binding proteins. Hood et 
al. reported that the rhythm of PER2 (period circadian 
regulator 2) expression could be modified by D2 
(dopamine-2) receptor activation [7]. Imbesi et al. 
found that D2 receptor agonists inhibited the 
expression of Clock and Per1 genes, while D1 receptor 
agonists enhanced the expression of Per1 and Clock 
genes [8]. 
On the other hand, Yujnovsky et al. reported a 
reduced transcription of the Per1 gene in D2R 
(dopamine D2 receptor)-null mice models [9]. 
Dopamine alteration can also impair the proper 
rhythm during the prenatal stage in the circadian 
pacemaker SCN [10, 11]. The light/dark alternation 
regulates the melatonin and the main mechanisms 
acting under the circadian rhythm: the melatonin acts 
as the main stimulator of the fetal SCN [12] and is also 
controlled by dopamine-receptor signaling [13]. 
This concise review aims to investigate the 
connection among some aspects of circadian rhythm 
related to the onset of Parkinson’s Disease (PD) and 
the extracellular vesicles released in PD patients.  
Finally, the authors will suggest how those 
exosomes derived from dopaminergic neurons, 
obtained by novel oral-derived stem cells may 
represent a smart model for the in vitro research on 
PD. 
Genetic, endogenous and environmental 
factors can impact PD onset and severity 
The genetic pathway involved in PD patho-
genesis depends on the type of genetic mutation. 
Currently, four genes are clearly involved in the 
autosomal dominant form of PD: the SNCA/PARK1- 
PARK4 gene, the LRRK2/PARK8 gene, the VPS35/ 
PARK17 gene, and the EIF4G1/PARK18 gene; on the 
other hand, PARK-1 and DJ-1 genes are typically 
involved in the autosomal recessive transmission. A 
combination of genetic predisposition and 
environmental factors is the most intriguing topic to 
understand the basis of PD early-onset; the chronic 
interaction with toxic substances in the living 
environment certainly increases the possibility to 
develop damages to the mitochondria, which are 
responsible for the increase of Reactive Oxygen 
Species (ROS) in the body, and which are closely 
associated with the production of misfolded 
α-Synuclein [14].  
Genetic mutations in the genes that code for 
PARKIN and PINK-1 are closely associated with PD 
and mitochondria alterations: these genetic alterations 
may be triggered by several factors, and they 
represent a crucial step in the onset of several 
neurodegenerative pathologies. In fact, mitochondria 
play a key role in cell metabolism, so that an impaired 
activity of the mitochondrial complexes has been 
widely reported in the Substantia Nigra of PD 
patients. Mitochondria are extremely susceptible to 
high levels of oxidative stress, often induced by the 
presence of ROS that may increase in such cases 
where mitochondria complexes work badly.  
It is well known that the formation of 
super-aggregates of misfolded and toxic accumula-
tion of α-synuclein is pathognomonic for PD: a point 
mutation of the SNCA gene, coding for α-synuclein, is 
related to oxidative stress and to impaired activity of 
serotonergic neurotransmitters, a dysfunction that 
occurs before the clinical diagnosis of Parkinson's 
disease.  
An abnormal accumulation of α-synuclein, due 
to genetic mutations of the related gene, can be cause 
and consequence of sleep-wake rhythm alterations. 
This correlation is not only a kind of side effect of PD 




symptomatology, but the sleep-wake rhythm 
alterations concretely influence the severity of PD, as 
a consequence of the primary alteration of the 
serotonergic system, in turn, associated to sleep 
dysfunction in PD [15].  
Circadian rhythm: a metronome able to 
modulate the content of the extracellular 
vesicles in PD patients 
Circadian rhythm (CR) is a natural metronome 
regulating gene expression in mammalian and 
eukaryotic cells.  
Exosomes have been reported to act in several 
processes: one of the most interesting is the RNA 
degradation [16], which is closely linked to the 
reduction of such proteins that plays a pivotal role in 
the peripheral control of those functions regulated by 
CR. The link between RNA degradation, CR and 
exosomes activity is closely related to the regulation 
of cell cycle, driving the early steps of cell 
development: the same cellular mechanism has been 
observed in both prokaryotic and eukaryotic, 
suggesting that this peculiar link has been conserved 
over the evolutionary development [17].  
The exosomes contain several bioactive 
molecules closely related to the CR activity: this 
evidence increasingly promoted studies aimed to 
understand the real involvement of EVs in the 
synchronization between signals generated by the 
SNC and the peripheral effectors. It is biologically 
reasonable that exosomes could act as carriers of 
information across the intricate clock circuits [18].  
CR is often related to the onset of several 
neurodegenerative diseases; in fact, the CR alteration 
seems to anticipate the clinical symptoms of cognitive 
and non-cognitive impairments [19]. Exosomes could 
be considered as therapeutic tools, able to control and 
preserve the CR integrity: they could be potentially 
used for the treatment of such diseases linked to 
impairments of CR. Although there is contrasting 
evidence, the link between CR alteration, exosomes 
impairment and neurological diseases may be a 
consequence of multiple alterations of specific 
proteins production; moreover, the pathogenesis may 
be triggered by immunological dysfunctions [20].  
In this context, recent studies have consistently 
demonstrated that exosomes secreted by PD neurons 
spread the α-synuclein (α-syn), a pathognomonic 
protein secreted by neurons representing the main 
component of Lewy’s bodies; moreover, PD-related 
exosomes can increase neuroinflammation, thus 
playing a role in PD worsening [21]. 
PD develops its clinical signs starting from a 
massive degeneration of dopaminergic neurons (DA) 
located in the human brain. Intracellular proteins 
alteration is potentially involved in the common 
pathogenesis of PD: these alterations mainly involve 
endosomes and lysosomes [22]. In this context, the 
secretion of extracellular vesicles (EVs), specifically 
the exosomes, is influenced by processes that 
modulate the protein synthesis: in PD, the EVs 
content represents a "snapshot" of the intracellular 
environment, selecting molecules acting as 
biomarkers in the local microenvironment [23]. 
Exosomes and their content are typically involved in 
cell-to-cell communication, acting as shuttles of 
molecules that can influence target-cells with 
biomarkers (miRNAs, proteins, lipids). PD patients 
have been reported to have impaired expression of 
genes related to CR [24]. 
Moreover, PD patients have an altered secretion 
pattern of melatonin, especially PD, with a non- 
tremor-dominant phenotype. A potential explanation 
of the link among CR and PD onset could be partially 
related to the significant reduction of Period 
Circadian Regulator 1 and Brain and Muscle 
ARNT-Like 1 expression in leucocytes. Dopamine 
seems to have a central role in this mechanism: in fact, 
it can affect the BMAL1/CLOCK heterodimer 
activity, thus modulating one of the most strategic 
molecular players working in CR [25].  
Recent studies have pointed out that neurons of 
PD patients are also subjected to several alterations of 
mitochondria and endoplasmic reticulum, combined 
with alterations in the proteosome-ubiquitin system, 
leading to the onset of such neurodegenerative 
disease. Moreover, PD patients frequently show 
severe dysfunctions in the mitochondrial metabolism 
of Ca2+. Specifically, Parkin is an E3 ubiquitin-protein 
ligase, able to modulate Ca2+ mitochondrial 
homeostasis: it is involved in the binding between the 
ubiquitin and the polypeptide-chains. On the other 
hand, it has been also demonstrated that the 
expression of mutant forms of Parkin might affect the 
structure and the physiology of endosomes and 
endo-lysosomal pathway: such mutations are peculiar 
of PD patients, which frequently show an increase in 
the releasing of exosomes [26].  
PD patients have the typical loss of Parkin: this 
anomaly has been related to a decrease in endosomal 
tubulation and an increased formation of intraluminal 
vesicles, coupled with a greater release of exosomes 
[27]. This impaired mechanism stimulates Parkin to 
regulate the Rab7 levels: in fact, Rab7 is highly 
expressed in Parkin-free cells, and it is also fatally 
associated with the increased production of exosomes, 
suggesting that Rab7 deregulation may be partially 
responsible for the endocytic phenotype observed in 
Parkin-deficient cells [28].  
Mitochondrial damage in PD has been reported 




to be frequently related to the interaction between 
PINK1 and Parkin [29,30]. PINK1 activates the 
phosphorylation of ubiquitin of the outer 
mitochondrial membrane: this phosphorylation 
activates Parkin, which consequently increases its 
ubiquitin ligase activity; as a consequence of this 
pathway, Parkin promotes the cellular autophagy and 
the formation of vesicles derived from damaged 
mitochondria [29]. Parkin and PINK1 appear to be 
mutated in familial Parkinson's disease. Furthermore, 
Parkin and PINK1 inhibit the molecular mechanisms 
leading to the presentation of the mitochondrial 
antigen (MitAP) by blocking the transport of vesicles 
derived from mitochondria (MDV) [30].  
This association among Parkin, PINK1, 
mitochondrial damage, and impaired production of 
exosomes after mitochondrial autophagy in PD cells 
strongly suggests that the studies based on exosomes 
from PD cell-models are a strategic way to carry out 
novel results on this severe neurodegenerative 
disease. A strategic future challenge would be to 
investigate whether CR alteration is able to influence 
the PD onset, or if it should be considered only a risk 
factor. In fact, impairment of CR impacts the 
expression of several genes, and it can locally trigger 
inflammatory responses, oxidative stress, and it can 
also impair the degradation of protein aggregates that 
play a pivotal role in neuroinflammation and 
neurodegeneration [31]. 
The human Periapical-Cyst-Mesenchymal 
Stem Cells (hPCy-MSCs): a novel MSC line 
Recent studies have shown that MSCs can also 
differentiate towards phenotypes of great clinical 
interest, such as neuron-like phenotype [32, 33].  
MSCs residing in the oral cavity are commonly 
defined as "Oral Derived-MSCs" (ODSCs) [34]: 
recently, the authors have discovered ODSCs even in 
inflamed periapical cysts [35]; these cells have been 
characterized and called human Periapical-Cyst- 
Mesenchymal Stem Cells (hPCy-MSCs). Further 
studies demonstrated that such cells are a promising 
tool in regenerative medicine [36, 37]. 
HPCy-MSCs express a specific panel of surface 
markers, such as CD13, CD29, CD44, CD73, CD105, 
CD90 and STRO-1 [38,39]; moreover, these cells have 
high plasticity and they can easily differentiate 
towards adipose and cartilaginous cells, towards 
osteoblasts and neurons [40]. 
Immunofluorescence and cytofluorimetry 
analyses on hPCy-MSCs have found that they naively 
express the main neuronal markers, such as β-III 
tubulin, and the main astrocytes markers, such as glial 
fibrillary acidic protein (GFAP). Gene expression in 
hPCy-MSCs exposed to neurogenic culturing 
conditions showed a notable increase in neural 
markers: surprisingly, these cells preferentially 
differentiate towards dopaminergic neurons, already 
after 21 days of culture in the neuro-inductive 
medium [41].  
The spontaneous commitment of these cells 
towards neuronal differentiation and in particular 
towards the formation of dopaminergic neurons 
raises interesting implications in the development of 
new therapies involving hPCy-MSCs, as could be the 
development of Parkinson's cell models to explore the 
biochemical pathways involved in the onset of the 
disease in an in vitro system. 
The advantages of using hPCy-MSCs, compared 
with plasma samples, are related to the easy 
procedure for isolating MSCs from a tissue that would 
otherwise be eliminated (this is the key- concept of the 
so-called “waste medicine”): this main advantage is 
certainly not to be underestimated. In fact, the 
possibility of using a "biological waste", represented 
by each discarded tissue usable in reparative/ 
regenerative medicine, that becomes a rich source of 
stem cells represents an important opportunity to 
highly evaluate these cells in regenerative procedures 
[42].  
On the other hand, hPCy-MSCs are abundant 
and easy to find within biological tissue, usually 
discharged: moreover, hPCy-MSCs have been 
demonstrated to have similar stemness properties of 
the well-known dental pulp stem cells, thus making 
them safe and reliable in tissue engineering. 
The releasing of extracellular vesicles (EVs) 
content has been considered a strategy makes cells 
able to eliminate harmful compound; furthermore, 
recent researches have suggested that EVs act as a 
bridge among CR effectors and targets, just like a kind 
of messengers of eukaryotic cells. EVs are transporters 
of several biological molecules, and they are released 
in the extracellular environment, both in pathological 
and physiological conditions [43].  
Typically, the exosome’s content includes nucleic 
acids, cytokines, proteins, and enzymes, misfolded 
proteins [44].  
Numerous studies carried out in the last years 
have confirmed the role of exosomes in modulating 
several neuronal activities: a pivotal role of these 
vesicles has been described in the synaptic activity 
among different neurons, confirming the commitment 
of these extracellular messengers [45].  
An increased number of exosomes in the 
substantia nigra has been often related to several 
neurodegenerative diseases; in PD, scientists have 
observed an increased number of exosomes that 
mainly transport α-synuclein to target cells, inducing 
their apoptosis. This strategy may suggest that 




exosomes’ content plays a key role in the worsening of 
clinical conditions suffered by patients with PD. In 
fact, the spreading of α-synuclein and its aggregates 
in the brain can be considered as one of the main steps 
towards the PD progression. On the other hand, some 
authors also reported that exosomes could be strategic 
actors for targeted therapy in PD patients, as they can 
act as a shuttle for the local drug-releasing and their 
content has been carefully investigated to discover 
new biomarkers for PD [46].  
In the familiar PD, α-synuclein aggregates are 
typically observable and known as “Lewy bodies”. 
Interestingly, the overall α-synuclein-mRNA levels 
increase in PD mid-brain, but they do not change in 
the PD patient’s frontal cortex. In this landscape, 
exosomes are the main actors in the releasing of 
biological molecules to target cells located in different 
areas of the brain. In fact, these small carriers can 
contribute to PD propagation, through spreading the 
misfolded α-synuclein from affected cells to normal 
cells [47].  
In PD, the degeneration of dopaminergic 
neurons depends on the pathological accumulation of 
such misfolded and toxic forms of α-synuclein in the 
cytoplasm: neuron-derived exosomes are also able to 
carry α-synuclein toxic forms to astrocytes and 
microglia, so contributing to PD spreading also as a 
consequence of inflammatory mechanisms. In the 
light of the consistent impact of neuron-derived 
exosomes and their contents to PD, these markers can 
be the most useful in a strategy aimed to improve the 
early diagnosis and to find novel therapeutic 
strategies for PD in a cell-model, as we suggest in this 
review. 
Dopaminergic neurons (DA) could be obtained 
after the exposition of hPCy-MSCs to neural-inductive 
medium; the isolation of exosomes from the condi-
tioned culture medium is currently standardized [48]. 
The characterization of the exosomes content could be 
obtained using electron microscopy, cytofluorimetry, 
and western blotting: it has been shown that 
exosomes carry a series of molecules from one cell to 
another; a strategic diagnostic approach could be 
based on the analysis of microRNAs in plasma and 
circulating exosomes. In fact, microRNAs are a class 
of RNA molecules that, due to their small size, can 
cross the blood-brain barrier and appear in the 
bloodstream so their role can be relevant for PD in the 
initial stages (asymptomatic) and the various phases 
of development [49,50]. 
The isolation of the exosomes from hPCy-MSCs 
will allow several analyses on miRNAs through 
microarrays and gene sequencing. The analysis of 
small-sized circulating exosome-derived micro-RNA 
could be usefully associated with nanotechnologies: 
this is important to improve the ability of novel smart 
nanomaterials to intercept the ultralow-molecular- 
weight biomolecules, so acting as a theranostic tool 
with high sensitivity and high specificity [51,52].  
In this light, the isolation, purification, and 
characterization of those molecules enclosed in 
hPCy-MSCs-derived exosomes, and released in the 
culture medium, may provide important information 
on biomarkers usable for the early diagnosis and the 
monitoring of neurodegenerative diseases, with a 
special interest toward PD.  
In this landscape, hPCy-MSCs-derived exosomes 
are a kind of experimental platform for analyzing and 
developing novel therapies, based on the study of 
molecules carried by these extracellular vesicles.  
Conclusions and future insights  
As properly described in this review, several 
scientific pieces of evidence have clearly shown that 
impairments in the CR can play a pivotal role in the 
pathogenesis of neurodegenerative diseases. Altered 
expression of clock genes has been found in the 
peripheral blood cells of PD patients [25].  
Exosomes contain and transport several types of 
molecules, including membrane proteins and 
cytosolic proteins, messenger RNAs, and ncRNAs 
(such as miRNAs): the ability to share information 
among neurons is mediated by such exosomes, 
released in the surrounding environment. 
In this context, the characterization of the 
exosomes released in the culture medium of 
dopaminergic neurons differentiated from hPCy- 
MSCs could represent an interesting strategy. 
We hypothesized that the hPCy-MSCs, properly 
differentiated into dopaminergic neurons, could be 
characterized by specific markers. Following the 
differentiation of hPCy-MSCs into neurosecretory 
dopaminergic neurons, the characterization of the 
exosomes may be performed both on neurons 
differentiated by hPCy-MSCs obtained from healthy 
subjects and by subjects affected by PD. The existence 
of a potential link among the alteration of circadian 
rhythm and the onset of PD has been proposed in the 
scientific literature. The genes involved in circadian 
rhythm are regulated by secreted molecules, 
embedded in extracellular vesicles; thus, the study of 
the secretory pattern of cells from healthy subjects and 
patients affected by PD could help the researchers to 
understand better those mechanisms that may 
correlate the circadian rhythm and the onset of PD. In 
this landscape, the possibility of using a new smart 
source of MSCs derived from the inflamed periapical 
cysts, that have previously and consistently showed a 
spontaneous tendency to neural differentiation, could 
represent an advantageous and free-of-biological- 




costs model for novel and highly repetitive in vitro 
investigations, to find new biomarkers, to test new 
drugs or, fatally, to find new pathways to use in novel 
therapeutic approaches.  
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